~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) --…
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH)…
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted…
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology…
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary…
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and…
FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026…
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms…
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against…
TARA-002 selected for FDA manufacturing development and readiness pilot programNEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc.…